SEC Form 4 · accession 0001618835-18-000018
Evofem Biosciences, Inc. · EVFM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas G Lynch
Director
Period of report
May 8, 2018
Accepted (ET)
May 9, 2018 · 6:35 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001618835
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $6.99 | May 8, 2018 | A | 12,875 | A | — | May 8, 2028 | Common Stock | 12,875 | 12,875 | D |
Explanation of responses
- F1The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of May 8, 2018. The option was awarded in connection with Mr. Lynch's board and committee services.